Status:
COMPLETED
Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
Lead Sponsor:
Sohag University
Conditions:
Spontaneous Bacterial Peritonitis
Eligibility:
All Genders
18-80 years
Brief Summary
Current reports have demonstrated that copeptin predicts disease progression and prognosis in cirrhotic patients, independent of liver-specific scoring systems. To the best of our knowledge, few studi...
Eligibility Criteria
Inclusion
- The diagnosis of liver cirrhosis will be based on clinical data and findings on abdominal ultrasound. The diagnosis of SBP will be based on the presence of at least 250 cells/ml PMNLs in the ascitic fluid, with or without positive ascitic fluid culture in the absence of hemorrhagic ascites and secondary peritonitis
Exclusion
- Patients with heart failure, coronary insufficiency, advanced chronic respiratory disease, polyuria-polydipsia syndrome and hypotension or shock.
- Patients with chronic kidney disease treated with hemodialysis before admission.
- Patients with previous liver or kidney transplantation.
- Patients with intraabdominal malignancy.
- Patients with severe infection other than SBP.
- Patients who had received antibiotics before hospital admission.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT05401721
Start Date
May 1 2021
End Date
December 1 2021
Last Update
June 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag Faculty of Medicine
Sohag, Egypt, 82524